<p>不幸的是，对于一些股东来说，<strong>C4 Therapeutics, Inc.</strong>（纳斯达克代码：CCCC）的股价在过去三十天内下跌了 40%，延续了近期的痛苦。对于任何长期股东来说，上个月的表现结束了一个令人遗忘的年份，锁定了 82% 的股价下跌。</p>
<p>在经历如此大幅的价格下跌后，C4 Therapeutics 目前可能看起来是一个强有力的买入机会，其市销率（&#34;P/S&#34;）为 2.5 倍，考虑到美国生物技术行业几乎一半的公司市销率超过 8.8 倍，甚至市销率超过 51 倍的情况也并不罕见。不过，仅仅将市销率视为表面值并不明智，因为可能有解释说明其如此有限的原因。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 C4 Therapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761"/></p>
<p>纳斯达克 GS:CCCC 市销率与行业比较 2025 年 4 月 18 日</p>
<h3>C4 Therapeutics 最近的表现如何？</h3>
<p>C4 Therapeutics 的表现可能更好，因为它的收入增长低于大多数其他公司。市销率可能较低是因为投资者认为这种乏善可陈的收入表现不会有所改善。如果你仍然喜欢这家公司，你会希望收入不会变得更糟，并且能够在它不受欢迎时买入一些股票。</p>
<p>如果你想了解分析师对未来的预测，你应该查看我们关于 C4 Therapeutics 的 <strong>免费</strong> 报告。</p>
<h2>C4 Therapeutics 是否有收入增长的预测？</h2>
<p>你真正会感到舒适的唯一情况是，当 C4 Therapeutics 的市销率如此低迷时，公司的增长明显落后于行业。</p>
<p>如果我们回顾过去一年的收入增长，公司实现了 71% 的可喜增长。然而，这还不够，因为最近三年期间公司总收入经历了 22% 的大幅下滑。因此，可以公平地说，最近的收入增长对公司来说是令人失望的。</p>
<p>展望未来，根据跟踪该公司的八位分析师的预测，收入预计将下滑，未来三年每年收缩 20%。当行业其他公司预计每年增长 173% 时，这并不好。</p>
<p>考虑到这一点，我们发现 C4 Therapeutics 的市销率与其行业同行非常接近。然而，收入的萎缩不太可能在长期内导致稳定的市销率。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
<h2>C4 Therapeutics 市销率的底线</h2>
<p>C4 Therapeutics 的股价几乎跌入深渊，其市销率也随之大幅下滑。通常情况下，我们会警告在做出投资决策时不要过于关注市销率，尽管它可以揭示市场其他参与者对公司的看法。</p>
<p>正如我们所怀疑的，我们对 C4 Therapeutics 分析师预测的审查显示，收入萎缩的前景正在导致其市销率低迷。目前，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。在这种情况下，很难看到股价在不久的将来强劲上涨。</p>
<p>那么其他风险呢？每家公司都有风险，我们发现了 <strong>C4 Therapeutics 的 4 个警告信号</strong>（其中 1 个令人担忧！）你应该了解。</p>
<p><strong>如果你对过去盈利增长稳健的公司感兴趣</strong>，你可能希望查看这份 <strong>免费</strong> 的其他盈利增长强劲且市盈率低的公司集合。</p>
<p>如果你想交易 C4 Therapeutics，请在专业人士信任的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的水平。</p>
<p>赞助内容</p>

CCCC

<p>C4 Therapeutics, Inc.（纳斯达克代码：CCCC）的股价在过去一个月内暴跌了 40%，年内累计下降了 82%。尽管其市销率（P/S）仅为 2.5 倍，显示出潜在的买入机会，但公司的收入增长令人失望，预测未来三年年均将下降 20%。分析师指出，低市销率反映了市场对未来收入表现的怀疑，因此短期内股价强劲反弹的可能性不大。此外，关于公司财务健康状况，还有四个警示信号需要考虑</p>

<p>Unfortunately for some shareholders, the <strong>C4 Therapeutics, Inc.</strong> (NASDAQ:CCCC) share price has dived 40% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last month ends a year to forget by locking in a 82% share price decline.</p>
<div class="lb-trans"><p>不幸的是，对于一些股东来说，<strong>C4 Therapeutics, Inc.</strong>（纳斯达克代码：CCCC）的股价在过去三十天内下跌了 40%，延续了近期的痛苦。对于任何长期股东来说，上个月的表现结束了一个令人遗忘的年份，锁定了 82% 的股价下跌。</p>
</div><p>After such a large drop in price, C4 Therapeutics may look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 2.5x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.8x and even P/S higher than 51x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.</p>
<div class="lb-trans"><p>在经历如此大幅的价格下跌后，C4 Therapeutics 目前可能看起来是一个强有力的买入机会，其市销率（&#34;P/S&#34;）为 2.5 倍，考虑到美国生物技术行业几乎一半的公司市销率超过 8.8 倍，甚至市销率超过 51 倍的情况也并不罕见。不过，仅仅将市销率视为表面值并不明智，因为可能有解释说明其如此有限的原因。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>See our latest analysis for C4 Therapeutics</p>
<div class="lb-trans"><p>查看我们对 C4 Therapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761" alt="" original-src="https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761"/></p>
<p>NasdaqGS:CCCC Price to Sales Ratio vs Industry April 18th 2025</p>
<div class="lb-trans"><p>纳斯达克 GS:CCCC 市销率与行业比较 2025 年 4 月 18 日</p>
</div><h3>How Has C4 Therapeutics Performed Recently?</h3>
<div class="lb-trans"><h3>C4 Therapeutics 最近的表现如何？</h3>
</div><p>C4 Therapeutics could be doing better as it's been growing revenue less than most other companies lately. The P/S ratio is probably low because investors think this lacklustre revenue performance isn't going to get any better. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>C4 Therapeutics 的表现可能更好，因为它的收入增长低于大多数其他公司。市销率可能较低是因为投资者认为这种乏善可陈的收入表现不会有所改善。如果你仍然喜欢这家公司，你会希望收入不会变得更糟，并且能够在它不受欢迎时买入一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on C4 Therapeutics.</p>
<div class="lb-trans"><p>如果你想了解分析师对未来的预测，你应该查看我们关于 C4 Therapeutics 的 <strong>免费</strong> 报告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For C4 Therapeutics?</h2>
<div class="lb-trans"><h2>C4 Therapeutics 是否有收入增长的预测？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as C4 Therapeutics' is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>你真正会感到舒适的唯一情况是，当 C4 Therapeutics 的市销率如此低迷时，公司的增长明显落后于行业。</p>
</div><p>If we review the last year of revenue growth, the company posted a terrific increase of 71%. However, this wasn't enough as the latest three year period has seen the company endure a nasty 22% drop in revenue in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>如果我们回顾过去一年的收入增长，公司实现了 71% 的可喜增长。然而，这还不够，因为最近三年期间公司总收入经历了 22% 的大幅下滑。因此，可以公平地说，最近的收入增长对公司来说是令人失望的。</p>
</div><p>Looking ahead now, revenue is anticipated to slump, contracting by 20% per annum during the coming three years according to the eight analysts following the company. That's not great when the rest of the industry is expected to grow by 173% each year.</p>
<div class="lb-trans"><p>展望未来，根据跟踪该公司的八位分析师的预测，收入预计将下滑，未来三年每年收缩 20%。当行业其他公司预计每年增长 173% 时，这并不好。</p>
</div><p>With this in consideration, we find it intriguing that C4 Therapeutics' P/S is closely matching its industry peers. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>考虑到这一点，我们发现 C4 Therapeutics 的市销率与其行业同行非常接近。然而，收入的萎缩不太可能在长期内导致稳定的市销率。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>The Bottom Line On C4 Therapeutics' P/S</h2>
<div class="lb-trans"><h2>C4 Therapeutics 市销率的底线</h2>
</div><p>Having almost fallen off a cliff, C4 Therapeutics' share price has pulled its P/S way down as well. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>C4 Therapeutics 的股价几乎跌入深渊，其市销率也随之大幅下滑。通常情况下，我们会警告在做出投资决策时不要过于关注市销率，尽管它可以揭示市场其他参与者对公司的看法。</p>
</div><p>As we suspected, our examination of C4 Therapeutics' analyst forecasts revealed that its outlook for shrinking revenue is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>正如我们所怀疑的，我们对 C4 Therapeutics 分析师预测的审查显示，收入萎缩的前景正在导致其市销率低迷。目前，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。在这种情况下，很难看到股价在不久的将来强劲上涨。</p>
</div><p>And what about other risks? Every company has them, and we've spotted <strong>4 warning signs for C4 Therapeutics</strong> (of which 1 is concerning!) you should know about.</p>
<div class="lb-trans"><p>那么其他风险呢？每家公司都有风险，我们发现了 <strong>C4 Therapeutics 的 4 个警告信号</strong>（其中 1 个令人担忧！）你应该了解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果你对过去盈利增长稳健的公司感兴趣</strong>，你可能希望查看这份 <strong>免费</strong> 的其他盈利增长强劲且市盈率低的公司集合。</p>
</div><p>If you're looking to trade C4 Therapeutics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你想交易 C4 Therapeutics，请在专业人士信任的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的水平。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

投资者对 C4 Therapeutics, Inc.（NASDAQ:CCCC）前景不看好，导致股价下跌 40%